Literature DB >> 9097737

The indications for and outcome in pediatric keratoplasty. A multicenter study.

M R Dana1, A L Moyes, J A Gomes, K M Rosheim, D A Schaumberg, P R Laibson, E J Holland, A Sugar, J Sugar.   

Abstract

PURPOSE: A multicenter study was undertaken to delineate the indications for and outcome of pediatric keratoplasty.
METHODS: The authors retrospectively studied 164 grafts in 131 eyes of 108 children younger than 12 years of age, with an average follow-up of 45 months. Multivariate linear and logistic regression was performed to evaluate potential risk factors for poor visual outcome and graft failure. Graft survival was depicted in terms of the Kaplan-Meier survival curve.
RESULTS: Corneal opacities were grouped into three diagnostic categories: congenital (64%), traumatic (17%), and acquired nontraumatic (19%) opacities. Overall graft survival was 80% at 12 months and 67% at 24 months postoperatively. There was no significant difference in retention of clarity among diagnostic groups. Vitrectomy-lensectomy, regrafts, and postoperative complications were associated significantly with poor allograft survival. Eighteen percent of all eyes had worse vision at the time of the last visit than preoperatively. Amblyopia treatment was the only independently significant prognosticator for visual improvement after surgery. Timing of keratoplasty was not demonstrated to be associated with visual outcome. Visual acuity in 33% of eyes that could be quantified was better than 20/200 at the last visit, whereas 62% of eyes retained full graft clarity.
CONCLUSION: The authors conclude that keratoplasty can be successful in most children, especially when combined with appropriate amblyopia management.

Entities:  

Mesh:

Year:  1995        PMID: 9097737     DOI: 10.1016/s0161-6420(95)30900-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  Penetrating keratoplasty in children: visual and graft outcome.

Authors:  K McClellan; T Lai; J Grigg; F Billson
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

2.  Successful visual rehabilitation after neonatal penetrating keratoplasty.

Authors:  R W Hertle; S E Orlin
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

3.  Keratocyte apoptosis and failure of corneal allografts.

Authors:  Clay Beauregard; Syed O Huq; Stefano Barabino; Qiang Zhang; Andrius Kazlauskas; M Reza Dana
Journal:  Transplantation       Date:  2006-06-15       Impact factor: 4.939

4.  Clinicopathological correlation of congenital corneal opacification using ultrasound biomicroscopy.

Authors:  K K Nischal; J Naor; V Jay; L D MacKeen; D S Rootman
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

5.  The Palisades of Vogt in Congenital Corneal Opacification (An American Ophthalmological Society Thesis).

Authors:  Ken K Nischal; Kira L Lathrop
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

6.  Quantification of allospecific and nonspecific corneal endothelial cell damage after corneal transplantation.

Authors:  S K Chauhan; U Jurkunas; T Funaki; M Dastjerdi; R Dana
Journal:  Eye (Lond)       Date:  2014-10-17       Impact factor: 3.775

7.  Boston Keratoprosthesis: expanding the boundaries.

Authors:  Mona Harissi-Dagher
Journal:  Digit J Ophthalmol       Date:  2011-11-03

8.  Long-term visual outcomes of penetrating keratoplasty for Peters anomaly.

Authors:  Ji Woong Chang; Mee Kum Kim; Jeong Hun Kim; Seong-Joon Kim; Won Ryang Wee; Young Suk Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-04       Impact factor: 3.117

9.  Photorefractive keratectomy for anisometropic amblyopia in children.

Authors:  Evelyn A Paysse
Journal:  Trans Am Ophthalmol Soc       Date:  2004

10.  Descemet's stripping endothelial keratoplasty: is it an option for congenital hereditary endothelial dystrophy?

Authors:  Roberto Pineda; Vandana Jain; Debraj Shome; David C Hunter; Sundaram Natarajan
Journal:  Int Ophthalmol       Date:  2009-07-19       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.